Diabetes Care· 2018Q1· Guideline
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- 3,526citations
- Q1SCImago
- 2018year
Short summary
New 2018 ADA/EASD guidelines recommend SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit for type 2 diabetes patients with clinical cardiovascular disease, and SGLT2 inhibitors for those with chronic kidney disease or heart failure.
AI-generated from the title and abstract; the full text is not read.
Key points
- Updated guidelines emphasize lifestyle management and diabetes self-management education.
- For patients with clinical cardiovascular disease, SGLT2 inhibitors or GLP-1 receptor agonists with proven cardiovascular benefit are recommended.
- For patients with chronic kidney disease or heart failure, SGLT2 inhibitors with proven benefit are recommended.
- GLP-1 receptor agonists are generally recommended as the first injectable medication.
AI-generated from the title and abstract; the full text is not read.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education and support. For those with obesity, efforts targeting weight loss, including lifestyle, medication, and surgical interventions, are recommended. With regards to medication management, for patients with clinical cardiovascular disease, a sodium-glucose cotransporter 2 (SGLT2) inhibitor or a glucagon-like peptide 1 (GLP-1) receptor agonist with proven cardiovascular benefit is recommended. For patients with chronic kidney disease or clinical heart failure and atherosclerotic cardiovascular disease, an SGLT2 inhibitor with proven benefit is recommended. GLP-1 receptor agonists are generally recommended as the first injectable medication.
The authors' abstract, as published at the source. Diabetes Care, 2018 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Endocrinology, Diabetes and Metabolism
Endocrinology, Diabetes and MetabolismMedicine